X-TOLE2 Phase 3 is a study to see if a new drug called XEN1101 is safe and works well for people with focal-onset seizures. Focal-onset seizures are a type of epilepsy where seizures start in one area of the brain. In this study, some people will get XEN1101, and others will get a placebo, which looks like the medicine but doesn't have any active ingredients. This helps researchers see if the medicine makes a difference. You will need to take the medicine once a day with dinner for 12 weeks. If you finish, you may join a different study to keep getting XEN1101. You'll need to keep a diary of your seizures and have already tried other epilepsy medicines without success.

• The study lasts about 21.5 weeks, including 9.5 weeks of baseline and 12 weeks of treatment.
• You must already be taking 1 to 3 seizure medicines before joining.
• If you finish, you might join another study to keep getting the medicine.